Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody-Reference-Cited by-同舟云学术

Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody

Published:2008-02 Issue:3 Volume:140 Page:303-312
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Bleeker Wim K.,Munk Martin E.,Mackus Wendy J. M.,van den Brakel Jeroen H. N.,Pluyter Marielle,Glennie Martin J.,van de Winkel Jan G. J.,Parren Paul W. H. I.

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2007.06916.x/fullpdf

Reference27 articles.

1. Association of serum Rituximab (IDEC–C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin’s lymphoma

2. Accelerated autoantibody clearance by intravenous immunoglobulin therapy: studies in experimental models to determine the magnitude and time course of the effect

3. Potent antibody therapeutics by design

4. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

Cited by 79 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trpv6 channel targeting using monoclonal antibody induces prostate cancer cell apoptosis and tumor regression;Cell Death & Disease;2024-06-15

2. Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Multiple Sclerosis: A Review of Clinical Considerations;SN Comprehensive Clinical Medicine;2024-02-08

3. B cells in multiple sclerosis — from targeted depletion to immune reconstitution therapies;Nature Reviews Neurology;2021-06-01

4. A phase 3, randomized study of ofatumumab combined with bendamustine in rituximab‐refractory iNHL (COMPLEMENT A + B study);British Journal of Haematology;2021-05-10

5. Astrocytes in the pathogenesis of multiple sclerosis;Folia Pharmacologica Japonica;2021